# Tolerability and Steady-state Pharmacokinetics of BIA 6-512

> **NCT03093389** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 40 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** BIA 6-512
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03093389
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-11
- **Primary completion:** 2005-07-29
- **Final completion:** 2005-07-29
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093389, "Tolerability and Steady-state Pharmacokinetics of BIA 6-512". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03093389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*